Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates
Abstract Globally accessible therapeutics against SARS-CoV-2 are urgently needed. Here, we report the generation of the first anti-SARS-CoV-2 DARPin molecules with therapeutic potential as well as rapid large-scale production capabilities. Highly potent multivalent DARPin molecules with low picomolar virus neutralization efficacies were generated by molecular linkage of three different monovalent DARPin molecules. These multivalent DARPin molecules target various domains of the SARS-CoV-2 spike protein, thereby limiting possible viral escape. Cryo-EM analysis of individual monovalent DARPin molecules provided structural explanations for the mode of action. Analysis of the protective efficacy of one multivalent DARPin molecule in a hamster SARS-CoV-2 infection model demonstrated a significant reduction of pathogenesis. Taken together, the multivalent DARPin molecules reported here, one of which has entered clinical studies, constitute promising therapeutics against the COVID-19 pandemic..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 23. Juli Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.08.25.256339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018633595 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018633595 | ||
| 003 | DE-627 | ||
| 005 | 20230429082243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200827s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.08.25.256339 |2 doi | |
| 035 | |a (DE-627)XBI018633595 | ||
| 035 | |a (biorXiv)10.1101/2020.08.25.256339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Walser, Marcel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Globally accessible therapeutics against SARS-CoV-2 are urgently needed. Here, we report the generation of the first anti-SARS-CoV-2 DARPin molecules with therapeutic potential as well as rapid large-scale production capabilities. Highly potent multivalent DARPin molecules with low picomolar virus neutralization efficacies were generated by molecular linkage of three different monovalent DARPin molecules. These multivalent DARPin molecules target various domains of the SARS-CoV-2 spike protein, thereby limiting possible viral escape. Cryo-EM analysis of individual monovalent DARPin molecules provided structural explanations for the mode of action. Analysis of the protective efficacy of one multivalent DARPin molecule in a hamster SARS-CoV-2 infection model demonstrated a significant reduction of pathogenesis. Taken together, the multivalent DARPin molecules reported here, one of which has entered clinical studies, constitute promising therapeutics against the COVID-19 pandemic. | ||
| 700 | 1 | |a Rothenberger, Sylvia |e verfasserin |4 aut | |
| 700 | 1 | |a Hurdiss, Daniel L. |e verfasserin |4 aut | |
| 700 | 1 | |a Schlegel, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Calabro, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Fontaine, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Villemagne, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Paladino, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Hospodarsch, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Neculcea, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Cornelius, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Schildknecht, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Matzner, Mirela |e verfasserin |4 aut | |
| 700 | 1 | |a Hänggi, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Franchini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Schaible, Doris |e verfasserin |4 aut | |
| 700 | 1 | |a Schlegel, Iris |e verfasserin |4 aut | |
| 700 | 1 | |a Iss, Chloe |e verfasserin |4 aut | |
| 700 | 1 | |a Looser, Thamar |e verfasserin |4 aut | |
| 700 | 1 | |a Mangold, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Herzog, Christel |e verfasserin |4 aut | |
| 700 | 1 | |a Schiegg, Dieter |e verfasserin |4 aut | |
| 700 | 1 | |a Reichen, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Radom, Filip |e verfasserin |4 aut | |
| 700 | 1 | |a Bosshart, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Lehmann, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Haeuptle, Micha A. |e verfasserin |4 aut | |
| 700 | 1 | |a Zürcher, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Vagt, Toni |e verfasserin |4 aut | |
| 700 | 1 | |a Sigrist, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Straumann, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Proba, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Veitonmäki, Niina |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Keith M. |e verfasserin |4 aut | |
| 700 | 1 | |a Zitt, Christof |e verfasserin |4 aut | |
| 700 | 1 | |a Mayor, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Ryter, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Lyoo, Heyrhyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chunyan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wentao |e verfasserin |4 aut | |
| 700 | 1 | |a Drulyte, Ieva |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Wenjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Binz, H. Kaspar |e verfasserin |4 aut | |
| 700 | 1 | |a de Waal, Leon |e verfasserin |4 aut | |
| 700 | 1 | |a Stittelaar, Koert J. |e verfasserin |4 aut | |
| 700 | 1 | |a Taplin, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Seth |e verfasserin |4 aut | |
| 700 | 1 | |a Steiner, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a van Kuppeveld, Frank J.M. |e verfasserin |4 aut | |
| 700 | 1 | |a Engler, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Berend-Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Stumpp, Michael T. |e verfasserin |4 aut | |
| 700 | 1 | |a Amstutz, Patrick |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 23. Juli |
| 773 | 1 | 8 | |g year:2021 |g day:23 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.08.25.256339 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 23 |c 07 | ||
| 953 | |2 045F |a 570 | ||